Stock AnalizQuest Diagnostics (DGX) earnings for the quarter ended September 2026: EPS beats estimates
Quest Diagnostics reported results for the quarter ended September 2026 on October 22, 2026. Adjusted earnings per share came in at $3.00 against the analysts’ average forecast of $2.87, a beat of 4.4%.
Revenue for the quarter was $3.10 billion, up 10.0% from $2.82 billion in the same quarter a year earlier.
The market’s verdict: the stock rose 1.8% on the first trading day after the report.
The last four quarters
Quest Diagnostics has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $3.00 | $2.87 | +4.4% | +10% | +1.8% |
| Jun 2026 | $3.12 | $2.82 | +10.5% | +150% | +8.6% |
| Mar 2026 | $2.50 | $2.37 | +5.6% | −60% | +3.9% |
| Sep 2025 | $2.60 | $2.50 | +3.9% | −67% | −4.9% |
What comes next
Analysts expect EPS of $2.68 for the next quarter on average and $11.32 for the fiscal year ending December 31, 2026.
The average analyst price target is $257.27, 1% below the current price of $259.60.
Valuation and score
Quest Diagnostics scores 2.0 out of 5 overall on Stock Analiz (average), trades at a trailing P/E of about 25.9, and its intrinsic value under moderate assumptions is about 7% below the current market value. Full Quest Diagnostics analysis with 10 years of financials
Frequently asked questions
What was Quest Diagnostics’s EPS for the quarter ended September 2026?
$3.00 adjusted per share, against an analyst consensus of $2.87.
How much revenue did Quest Diagnostics report?
$3.10 billion, up 10.0% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.